From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q4 2022 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“在买家自己的采购、报销、处方集、规格、采购、网络、目录或计划系统中获得批准、指定、列入、合格、注册、报销或预先授权”的状态,从而使得未来业务的重要部分可以在没有每次单独销售事件的情况下到达,并且这种访问状态是新的,大部分量尚未反映在报告结果中。 在记录中,管理层讨论了CMS为皮肤替代品发布ASPs(平均销售价格)的影响。他们提到,2023年PuraPly产品将全年发布,这导致购买暂停,但预计随着产品进入全国推广,将带来增长。他们还说,非PuraPly产品预计增长28%,反映了新客户和单位销售的增长。然而,关键点是:管理层是否明确表示公司已进入一个“默认”路径,使得订单无需每次重新说服? 管理层提到“CMS发布ASPs”和“全国推广”等,但并未明确说公司已被列入某个批准供应商名单、处方集或报销目录,从而成为默认选择。他们更多是在讨论市场动态和竞争压力,以及产品发布后的预期增长。没有具体描述公司被纳入某个买方系统(如保险网络、医院处方集等)而成为默认选项。他们提到“全国推广”和“新客户”,但这仍是常规销售活动。 此外,管理层承认2023年收入指引基本持平,因为PuraPly下降被非PuraPly增长抵消。他们提到“非PuraPly产品增长28%”,但这可能只是销售增长,而非因为进入默认路径。 因此,没有证据表明公司已获得某种“批准、指定、列入”等状态,使得业务无需每次说服。管理层讨论的是市场挑战和竞争,而非公司已进入某个系统。所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.